Introduction
============

The International Diabetes Foundation predicted that by 2025, the Southeast Asia Region would have the highest prevalence of diabetes.[@b1-ppa-8-1185],[@b2-ppa-8-1185] In Malaysia, the Third National Health Morbidity Survey reported a drastic increase in the prevalence of diabetes, from 8.3% to 14.9%, among Malaysians aged 30 years and older within a 10-year period (1996--2006).[@b3-ppa-8-1185] The World Health Organization estimated that by 2030, Malaysia would have a total of 2.48 million individuals diagnosed with diabetes;[@b3-ppa-8-1185] however, this figure has already been surpassed, as in 2011, 2.6 million Malaysians had been diagnosed with diabetes.[@b2-ppa-8-1185],[@b4-ppa-8-1185] This increase in diabetes is a major concern, as the morbidity of people with diabetes is 11 times higher than the general population.[@b5-ppa-8-1185]

Diabetes mellitus is a lifelong chronic condition that requires self-management by individuals. Lifestyle modification and adherence to antidiabetes medications are the major determinants of therapeutic success in the management of diabetes.[@b6-ppa-8-1185] Studies demonstrate that poor glycemic control results in the development of long-term complications and was also associated with disease progression, hospitalization, premature disability, and mortality.[@b7-ppa-8-1185]--[@b9-ppa-8-1185] A study conducted in Malaysia found that 58% of people with diabetes had neuropathy, 53% had retinopathy, 8.6% had cardiovascular diseases, 5.6% had stroke, and 1.9% had amputation.[@b10-ppa-8-1185]

In addition, other studies have found a significant association between adherence to antidiabetes medications and glycemic control.[@b11-ppa-8-1185]--[@b17-ppa-8-1185] A study conducted in Malaysia found that 41.7% of people with diabetes did not adhere to their antidiabetes medications and that the odds of achieving glycemic control were two times higher among those who adhered to their antidiabetes medications compared with those who did not.[@b18-ppa-8-1185] Another study also concluded that those who were nonadherent to their medications had significantly higher levels of fasting blood glucose.[@b19-ppa-8-1185],[@b20-ppa-8-1185]

The roles of pharmacists within the health care system today have evolved from a product-centered approach to patient-centered care, which means the refocusing of time and energy on professional responsibilities.[@b20-ppa-8-1185]--[@b23-ppa-8-1185] Therefore, the fundamental goal of pharmacy practice today is to provide pharmaceutical care (PC).[@b24-ppa-8-1185] PC is the responsible provision of drug therapy via collaboration of a clinical pharmacist with the patient, as well as other members of the health care team, in designing, implementing, and monitoring a therapeutic plan that will produce specific outcomes. This includes identifying potential and actual drug-related problems, resolving current drug-related problems, and preventing future drug-related problems.[@b25-ppa-8-1185]

Studies on the effects of PC in the management of diabetes observed a statistically significant reduction in glycated hemoglobin (HbA~1c~) levels in the intervention group.[@b11-ppa-8-1185],[@b26-ppa-8-1185]--[@b34-ppa-8-1185] However, most of the studies in the literature were conducted in countries such as the United States, the United Kingdom, and Australia.[@b11-ppa-8-1185],[@b26-ppa-8-1185]--[@b34-ppa-8-1185]

The hypothesis is that although the provision of PC in Malaysia has increased gradually over the last 2 decades, a majority of pharmacists in Malaysia are still not intensively involved in patient care, and hence, such service is deemed to have a greater effect in Malaysia than in the developed countries, where the roles of pharmacists in patient care are already well-established. In addition, such studies are still scarce in developing countries such as Malaysia, and thus far, there is only one qualitative study that has been published with regard to PC.[@b35-ppa-8-1185] Therefore, the present study is warranted to investigate the effects of a PC model on medication adherence and glycemic levels of people with type 2 diabetes (T2DM).

Methods
=======

This is a prospective randomized controlled trial. The study was approved by the Medical Ethics Committee of the major teaching hospital involved in the study (MEC 757.112). Written, informed consent was obtained from all the participants on recruitment into this study.

Participants
------------

People who had been diagnosed with T2DM who were aged 21 years and older but were younger than 75 years, were taking at least one antidiabetes medication, were able to communicate in English, and had an HbA~1c~ level of 8% and above, could be included in this study. Any person with T2DM who visited the diabetes clinic of a major teaching hospital during the recruitment period and who fulfilled the inclusion criteria was requested to participate in this study. Participants' fasting blood glucose (FBG) levels and HbA~1c~ values were obtained from their medical records.

Participants' demographic and medical characteristics were collected via face-to-face interview and confirmed with participants' medical records. Medication adherence of participants was assessed using the validated Malaysian Medication Adherence Scale (MALMAS).[@b36-ppa-8-1185] MALMAS was developed and scored according to the Morisky Medication Adherence scale,[@b37-ppa-8-1185],[@b38-ppa-8-1185] on which the total score ranged from 0--8. Medication adherence was classified into three levels on the basis of the total scores obtained: low adherence (total score, \<6), medium adherence (total score, 6--7.9), and high adherence (total score, 8). In addition, medication adherence was classified into medication adherence (total score, 6--8) and nonadherence (total score, \<6).[@b36-ppa-8-1185]

Procedure
---------

Participants were allocated at random to the control or intervention groups. Participants in the intervention group received PC from a pharmacist, whereas those in the control group were provided standard pharmacy services, which consisted of dispensing the medications and providing brief instructions on how to take them. A pharmacist reviewed the medications of those in the intervention group and tried to resolve any drug-related problems encountered by the participants. In addition, participants in the intervention group were educated on diabetes, hypertension, and hyperlipidemia, as well as all aspects of their medications, with an emphasis on the importance of medication adherence. The intervention group was also given and taught how to use a pill box and a blood glucose meter to conduct self-monitoring of blood glucose at home and to record their readings. Participants in the intervention group received monthly follow-up telephone calls to help participants resolve any pharmaceutical care issues or drug-related problems.

All participants from both control and intervention groups were asked to return to the pharmacy for their next visit, which should preferably be about 3--4 months from the date of recruitment. Participants from both groups had their blood samples taken by a nurse and tested for FBG and HbA~1c~ levels by a certified clinical laboratory of the teaching hospital about a week before their next appointment for the study. Participants from the intervention group were counseled by a pharmacist regarding their blood glucose levels. If the participants did not have their blood glucose levels under control, then more stringent measures would be recommended after discussion with the participants' clinicians. Data were collected at recruitment (baseline) and then at 4, 8, and 12 months after recruitment. All interventions were conducted in accordance with a PC counseling and education checklist. Each intervention took approximately an hour at baseline, whereas subsequent visits took approximately half an hour for the pharmacist to provide counseling and education to each intervention participant.

In line with the UK Prospective Diabetes Study, a 1% reduction in HbA~1c~ level reduces the risk for myocardial infarction by 14%, that for microvascular complications by 37%, and that for diabetes-related deaths by 21%.[@b39-ppa-8-1185],[@b40-ppa-8-1185] Therefore, the present study would be deemed successful if a reduction of at least 1% in HbA~1c~ value could be achieved.

Statistical analysis
--------------------

All data were analyzed using PASW Statistics for Windows, version 18 (SPSS Inc., Chicago, IL, USA). Associations between categorical variables were analyzed using Pearson chi-square tests, whereas differences in clinical outcome measures (continuous variables) between the control and intervention groups were evaluated using independent *t*-test or Mann--Whitney *U*-test. Differences between baseline and endpoint outcome measures were determined using the paired *t*-test or Wilcoxon signed-rank test. The Generalized Estimating Equations (GEE) was used to analyze the predictors of the study outcomes, HbA~1c~, and medication adherence. Various parameters (such as participant's age, sex, ethnic group, education level, working status, income group, marital status, levels of exercise, body mass index \[BMI\] status, duration of diagnosis with diabetes, number of concurrent diseases, total number of prescribed medications, and whether in the control or intervention group) that may be associated with the study outcomes were included in the GEE analysis. Any *P*-value less than 0.05 was considered statistically significant.

Results
=======

A total of 241 participants were recruited for this study. The demographic and medical data of the participants are as shown in [Table 1](#t1-ppa-8-1185){ref-type="table"}. The thresholds for income groups were classified according to a household income survey conducted in Malaysia.[@b41-ppa-8-1185] In this survey, the middle-class income group was considered as from RM1,001 to RM5,000 per month. Therefore, in the present study, the middle-class group was divided into a lower middle-class income group (RM1,001--RM3,000) and an upper middle-class income group (RM3,001--RM5,000). The BMI of participants was categorized using international thresholds: healthy, 18.5--24.9 kg/m^2^; overweight, 25--29.9 kg/m^2^; and obese, 30 kg/m^2^ and above.[@b42-ppa-8-1185] The BMI of both control and intervention groups also did not show any significant difference at baseline. [Table 1](#t1-ppa-8-1185){ref-type="table"} shows a much higher proportion of participants with diploma and tertiary education in the intervention group compared with in the control group (42.5% vs 27.2%), although it was not statistically significant. Using the GEE analysis, it was found that education levels were not significantly related to medication adherence or HbA~1c~.

Medication adherence of participants was assessed using the MALMAS ([Table 2](#t2-ppa-8-1185){ref-type="table"}). Glycemic levels of participants are represented by FBG and HbA~1c~ ([Figures 1](#f1-ppa-8-1185){ref-type="fig"} and [2](#f2-ppa-8-1185){ref-type="fig"}). Using the Kolmogorov--Smirnov test, the *P*-values for all domains were less than 0.001, which implied that the data did not fulfil the normal distribution criteria. At baseline, there were no significant differences in demographic data and other characteristics, medication adherence, or glycemic levels between participants in the control and intervention groups ([Tables 1](#t1-ppa-8-1185){ref-type="table"} and [2](#t2-ppa-8-1185){ref-type="table"}; [Figures 1](#f1-ppa-8-1185){ref-type="fig"} and [2](#f2-ppa-8-1185){ref-type="fig"}).

Medication adherence
--------------------

Whether medication adherence was categorized into three (high, medium, and low adherence) or two (high or medium adherence, which are considered as adherent to medication, and low adherence, which is considered as nonadherence to medication) levels,[@b36-ppa-8-1185] there were significant associations between the levels of adherence and the provision of PC at months 4, 8, and 12 ([Tables 2](#t2-ppa-8-1185){ref-type="table"} and [3](#t3-ppa-8-1185){ref-type="table"}).

Outcomes of glycemic levels (FBG and HbA~1c~)
---------------------------------------------

Statistically significant differences in FBG and HbA~1c~ were observed between the control and intervention groups at 4 months after intervention, and these continued until the end of the study period (12 months; [Figures 1](#f1-ppa-8-1185){ref-type="fig"} and [2](#f2-ppa-8-1185){ref-type="fig"}). In addition, FBG and HbA~1c~ showed a statistically significant reduction from recruitment until the end of the study period (12 months after the provision of PC) for the intervention group, whereas the control group did not have any significant changes ([Table 4](#t4-ppa-8-1185){ref-type="table"}). At the end of the 12-month study period, there were significant differences between the percentage of the control and intervention groups who achieved FBG less than 6.2 mmol/L and HbA~1c~ levels less than 8% (FBG, 18.2% versus 31.7% \[chi-square, 5.859; *P*=0.015\]; HbA~1c~, 22.3% versus 47.5% \[chi-square, 16.831; *P*\<0.001\], respectively).

After accounting for confounding factors and interactions, the GEE analysis showed that the PC intervention was significantly related to a reduction in HbA~1c~ (Wald chi-square, 9.518; regression coefficient, B, −0.486 \[95% confidence interval (CI), −0.177 to −0.795\]; *P*=0.002) and an increase in medication adherence (Wald chi-square, 6.694; odds ratio, 1.903; 95% CI, 1.169--3.099; *P*=0.010).

Discussion
==========

The findings of the study show that the PC model used has a positive effect on medication adherence and on the glycemic control (FBG and HbA~1c~) of people with T2DM. There was no significant difference at baseline in terms of demographic and medical data between the control and intervention groups.

The present study has about 10% more female than male participants ([Table 1](#t1-ppa-8-1185){ref-type="table"}), but the Malaysian Third National Health Morbidity Survey and the International Diabetes Federation have shown that the prevalence of T2DM in males was comparable with that in females.[@b1-ppa-8-1185],[@b2-ppa-8-1185],[@b43-ppa-8-1185] The higher proportion of female participants may be because females with T2DM are more willing to participate in the study than males, as they are more likely to be nonworking housewives. The mean age of participants in this study is comparable with that in a previous study (59 versus 57.5 years old).[@b44-ppa-8-1185] The proportions of participants who are of Indian origin in this study is considered very high (33.5%), as this ethnic group in Malaysia only constitutes about 10% of its population. This corresponds with other studies that found that the prevalence of T2DM is highest among people of Indian origin.[@b2-ppa-8-1185],[@b43-ppa-8-1185]

The demographic and metabolic characteristics of the participants in this study are also similar to those obtained in the DiabCare Malaysia 2008 study.[@b43-ppa-8-1185] Approximately 25% of participants in the present study were overweight, whereas more than 50% were obese. This percentage is also comparable with that obtained from the DiabCare Malaysia 2008 study (mean BMI, 29 kg/m^2^ versus 27.8 kg/m^2^).[@b43-ppa-8-1185],[@b44-ppa-8-1185] The growing prevalence of obesity and overweight cases is closely linked to the upsurge in the number of diabetes cases. Approximately 90% of T2DM cases are attributed to being overweight.[@b43-ppa-8-1185],[@b44-ppa-8-1185] Therefore, counseling on lifestyle modification is essential in the management of diabetes.

At 4, 8, and 12 months after the provision of PC to the intervention group, there was significant association between the prevalence of medication adherence and whether the participants were in the intervention or control group ([Tables 2](#t2-ppa-8-1185){ref-type="table"} and [3](#t3-ppa-8-1185){ref-type="table"}). This implies that the provision of PC to the intervention group has improved medication adherence significantly.

The relationships among participants, health care providers, and social support are fundamental interpersonal factors that are closely related to medication adherence.[@b3-ppa-8-1185] In the present study, several consultations with the pharmacist enabled the development and establishment of a better patient--pharmacist professional relationship. These consultations increased the trust of the participants and hence may have contributed to improved medication adherence. Other studies also report that good communication between participants and health care providers leads to favorable and improved medication adherence among people with T2DM.[@b45-ppa-8-1185]

Participants in this study also had to manage complicated drug regimens, as more than 60% of the participants were receiving 6--10 medications. This increases the risk for an adverse event and/or a potential adherence issue. Therefore, continual assessment and surveillance by a pharmacist to identify and help these people resolve their drug-related problems is essential for the successful management of diabetes.

Significant improvements in glycemic control were observed at 4 months after implementing the PC model, and this was sustained until the end of the study. These findings are similar to those of other studies conducted in other countries.[@b46-ppa-8-1185]--[@b49-ppa-8-1185] This shows that the PC model used in this study was effective in improving the medication adherence and glycemic levels of patients with T2DM.

Nonetheless, the average mean values of FBG and HbA~1c~ of the participants were still above the recommended target range at the end of the study period. This may be because of the high baseline values during the recruitment period (mean of control: FBG, 9.2 mmol/L; HbA~1c~, 9.5%; intervention: FBG, 9.4 mmol/L; HbA~1c~, 9.6%). However, the proportion of participants in the intervention group who achieved HbA~1c~ levels less than 8% at the end of the study period was significantly higher than that of the control group. In addition, the results showed that the intervention participants achieved a mean reduction in HbA~1c~ of 1.4% (going from 9.6%--8.2% at the end of the study period). Therefore, this reduction is considered clinically significant, and the PC model is deemed to be successful.

For each 10% increase in adherence, HbA~1c~ decreased significantly by 0.14%--0.16%.[@b50-ppa-8-1185] However, in the present study, HbA~1c~ improved by 1.4%, whereas the adherence levels improved by 5%. Nonetheless, this indicates the importance of emphasizing medication adherence as part of a diabetes management program.

The GEE model shows that the PC intervention has a significant positive effect on HbA~1c~ values and on the medication adherence of people with T2DM. The odds of the intervention participants being adherent to their medications were almost double the odds for those who did not receive pharmaceutical care. This further confirms the importance of providing pharmaceutical care services as a component of diabetes management.

Limitations of the study
------------------------

One of the limitations of this study was that it was conducted in English only. However, Malaysia is a multiracial society with three main ethnic groups: Malays, Chinese, and Indians. Therefore, the results may not be representative of T2DM patients who cannot communicate in English.

In addition, the study was conducted only in a single hospital, and hence the results could not be generalized to T2DM patients in other hospitals and in community pharmacy settings, although the demographic data of the participants corresponds with those of other studies. There may also be cross-contamination between participants in the control and intervention groups that could not be avoided, as they were attending the same clinic. Control participants may have discussed the study with the intervention participants and obtained some information regarding their disease conditions and medications. Therefore, the effects of the PC intervention may have been diluted. In addition, the implementation of this PC model on a wider scale may be limited by the health care infrastructure, as well as possibly cost and patients' access to health care facilities.

The participants were followed-up for only one year due to limited study time frame, which may not be adequate to detect long-term diabetes complications, and hence the long-term benefits of the PC model used in this study could not be determined.

Conclusion
==========

The collaborative efforts between pharmacists and other health care professionals through the provision of PC, as demonstrated in this study, has positive effects on medication adherence and glycemic levels of people with T2DM. Therefore, the PC model used in this study should be duplicated in other health care settings for the benefit of more people with T2DM. Further studies can be conducted to evaluate the long-term effects of PC, as well as the cost-effectiveness of such services.
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![Comparison of FBG between control and intervention groups over time (shown as median in the graph).\
**Notes:** *z*-value, Mann--Whitney *U*-test, \*statistically significant at *P*\<0.05; \*\**P*\<0.01.\
**Abbreviations:** FBG, fasting blood glucose; C, control group; I, intervention group; n, number of participants in each group.](ppa-8-1185Fig1){#f1-ppa-8-1185}

![Comparison of HbA~1c~ values between control and intervention groups over time (shown as median in the graph).\
**Notes:** *z*-value, Mann--Whitney *U*-test, \*statistically significant at *P*\<0.05; \*\**P*\<0.01.\
**Abbreviations:** HbA~1c~, glycated hemoglobin; C, control group; I, intervention group; n, number of participants in each group.](ppa-8-1185Fig2){#f2-ppa-8-1185}

###### 

Characteristics of participants

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographic data\                                                                           Frequency (%)     *χ*^2^ (*P*-value)   *z* value[\#](#tfn1-ppa-8-1185){ref-type="table-fn"} (*P*-value)   
  (N=241)                                                                                                                                                                                               
  ------------------------------------------------------------------------------------------- ----------------- -------------------- ------------------------------------------------------------------ ----------------
  Sex                                                                                                                                                                                                   

   Male                                                                                       56 (46.3%)        50 (41.7%)           0.521 (0.471)                                                      

   Female                                                                                     65 (53.7%)        70 (58.3%)                                                                              

  Age in years, mean ± SD (median)                                                            58.5±8.3 (59.0)   59.7±9.5 (59.5)                                                                         −1.132 (0.258)

   21--50                                                                                     20 (16.5%)        17 (14.2%)           1.505 (0.471)                                                      

   51--60                                                                                     53 (43.8%)        46 (38.3%)                                                                              

   61--75                                                                                     48 (39.7%)        57 (47.5%)                                                                              

  Ethnic group                                                                                                                                                                                          

   Malay                                                                                      47 (38.8%)        61 (50.8%)           4.830 (0.089)[@](#tfn2-ppa-8-1185){ref-type="table-fn"}            

   Chinese                                                                                    23 (19.0%)        26 (21.7%)                                                                              

   Indian                                                                                     47 (38.8%)        32 (26.7%)                                                                              

   Others                                                                                     4 (3.3%)          1 (0.8%)                                                                                

  Marital Status                                                                                                                                                                                        

   Single                                                                                     4 (3.3%)          4 (3.3%)             3.089 (0.378)                                                      

   Married                                                                                    97 (80.2%)        98 (81.7%)                                                                              

   Divorced                                                                                   7 (5.8%)          2 (1.7%)                                                                                

   Widower                                                                                    13 (10.7%)        16 (13.3%)                                                                              

  Level of education                                                                                                                                                                                    

   None and primary                                                                           13 (10.7%)        8 (6.7%)             6.637 (0.084)                                                      

   Secondary                                                                                  75 (62.0%)        61 (50.8%)                                                                              

   Diploma                                                                                    16 (13.2%)        27 (22.5%)                                                                              

   Tertiary and postgraduate                                                                  17 (14.0%)        24 (20.0%)                                                                              

  Working status                                                                                                                                                                                        

   Yes                                                                                        50 (41.3%)        48 (40.0%)           0.044 (0.834)                                                      

   No                                                                                         71 (58.7%)        72 (60.0%)                                                                              

  Income per month                                                                                                                                                                                      

   ≤ RM1,000 (USD\$309)                                                                       48 (39.7%)        49 (40.8%)           6.826 (0.234)                                                      

   RM1,001--3,000 (USD\$310--\$929)                                                           45 (37.2%)        47 (39.2%)                                                                              

   RM3,001--5,000 (USD\$930--\$1,548)                                                         24 (19.8%)        14 (11.7%)                                                                              

   ≥ RM5,001 (USD\$1,549)                                                                     4 (3.3%)          10 (8.3%)                                                                               

  Body mass index in kg/m^2^[@@](#tfn3-ppa-8-1185){ref-type="table-fn"}, mean ± SD (median)   29.1±7.0 (28.4)   29.3±6.3 (28.0)                                                                         −0.288 (0.773)

   Underweight to healthy weight                                                              27 (23.5)         21 (18.4)            1.917 (0.383)                                                      

   Overweight                                                                                 44 (38.3)         58 (50.9)                                                                               

   Obese                                                                                      44 (38.3)         35 (30.7)                                                                               

  Number of times patient exercises in a week                                                                                                                                                           

   ≤ Once a week                                                                              43 (35.5%)        35 (29.2%)           2.208 (0.331)                                                      

   Twice a week                                                                               10 (8.3%)         16 (13.3%)                                                                              

   ≥ Three times a week                                                                       68 (56.2%)        69 (57.5%)                                                                              

  Duration of diabetes in years, mean ± SD (median)                                           16.3±8.0 (15.0)   16.3±8.0 (15.0)                                                                         −0.112 (0.911)

   0--10 years                                                                                28 (23.1%)        30 (25.0%)           0.623 (0.732)                                                      

   11--20 years                                                                               52 (43.0%)        55 (45.8%)                                                                              

   \>20 years                                                                                 41 (33.9%)        35 (29.2%)                                                                              

  Number of concurrent diseases                                                                                                                                                                         

   0                                                                                          38 (31.4%)        30 (25.0%)           2.578 (0.765)                                                      

   1                                                                                          31 (25.6%)        41 (34.2%)                                                                              

   2                                                                                          34 (28.1%)        33 (29.5%)                                                                              

   \>3                                                                                        18 (14.9%)        16 (13.3%)                                                                              

  Number of prescribed medications, mean ± SD (median)                                        6.1±2.2 (6.0)     6.4±2.1 (6.0)                                                                           −0.247 (0.805)

   0--5 types                                                                                 47 (38.8%)        41 (34.2%)           0.568 (0.451)                                                      

   ≥6 types                                                                                   74 (61.2%)        79 (65.8%)                                                                              

  Medications prescribed at baseline                                                                                                                                                                    

   Alpha-glucosidase inhibitor                                                                9 (3.5%)          17 (6.7%)            0.287[\^](#tfn4-ppa-8-1185){ref-type="table-fn"} (0.866)           

   Biguanide                                                                                  108 (41.9%)       105 (41.2%)                                                                             

   Dipeptidyl peptidase-4 inihibitor                                                          2 (0.8%)          0 (0%)                                                                                  

   Meglitinide                                                                                1 (0.4%)          0 (0%)                                                                                  

  Medications prescribed at baseline                                                                                                                                                                    

   Sulphonylurea                                                                              39 (15.1%)        36 (14.1%)                                                                              

   Thiazolidinedione                                                                          3 (1.2%)          2 (0.8%)                                                                                

   Insulin                                                                                    96 (37.2%)        95 (37.3%)                                                                              

   Incretin mimetic                                                                           0 (0%)            0 (0%)                                                                                  

  Medications prescribed at the twelfth month                                                                                                                                                           

   Alpha-glucosidase inhibitor                                                                3 (1.2%)          11 (4.5%)            2.024[\^](#tfn4-ppa-8-1185){ref-type="table-fn"} (0.567)           

   Biguanide                                                                                  103 (41.9%)       94 (38.5%)                                                                              

   Dipeptidyl peptidase-4 inhibitor                                                           6 (2.4%)          7 (2.9%)                                                                                

   Meglitinide                                                                                0 (0%)            0 (0%0                                                                                  

   Sulphonylurea                                                                              32 (13.0%)        35 (14.3%)                                                                              

   Thiazolidinedione                                                                          1 (0.4%)          0 (0%)                                                                                  

   Insulin                                                                                    100 (40.7%)       95 (38.9%)                                                                              

   Incretin mimetic                                                                           1 (0.4%)          2 (0.8%)                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Mann--Whitney *U*-test is used for continuous variables; *χ*^2^, chi-square test used for categorical variables

chi-square value was obtained by omitting the ethnic group "Others"

healthy weight range, 18.5--24.9 kg/m^2^; overweight, 25--29.9 kg/m^2^; obese, ≥30 kg/m^2^

chi-square value was obtained by analyzing the major classes of antidiabetes agents (biguanide, sulfonylurea, and insulin), as the sample size for the other classes was very small.

**Abbreviation:** N, total participants in the study; n, number of participants in each group; SD, standard deviation.

###### 

Comparison of medication adherence between control and intervention groups based on three levels of adherence

  Medication adherence   Frequency (%)   *χ*^2^ (*P*-value)   
  ---------------------- --------------- -------------------- ----------------------------------------------------------
  Baseline               n=121           n=120                1.900 (0.387)
   Low adherence         43 (35.5%)      36 (30.0%)           
   Medium adherence      43 (35.5%)      53 (44.2%)           
   High adherence        35 (28.9%)      31 (25.8%)           
  Month 4                n=109           n=115                7.310 (0.026)[\*](#tfn6-ppa-8-1185){ref-type="table-fn"}
   Low adherence         48 (44.0%)      31 (27.0%)           
   Medium adherence      35 (32.1%)      52 (44.3%)           
   High adherence        26 (23.9%)      33 (28.7%)           
  Month 8                n=110           n=102                7.289 (0.026)[\*](#tfn6-ppa-8-1185){ref-type="table-fn"}
   Low adherence         46 (41.8%)      25 (24.5%)           
   Medium adherence      33 (30.0%)      37 (36.3%)           
   High adherence        31 (28.2%)      40 (39.2%)           
  Month 12               n=121           n=120                8.182 (0.017)[\*](#tfn6-ppa-8-1185){ref-type="table-fn"}
   Low adherence         50 (41.3%)      30 (25.0%)           
   Medium adherence      41 (33.9%)      45 (37.5%)           
   High adherence        30 (24.8%)      45 (37.5%)           

**Notes:**

Statistically significant at *P*\<0.05. *χ*^2^, chi-square test.

**Abbreviations:** n, total number of participants in each group.

###### 

Comparison of medication adherence between control and intervention groups when classified as nonadherence and adherence

  Adherence/nonadherence   Frequency (%)   *χ*^2^ (*P*-value)   
  ------------------------ --------------- -------------------- ----------------------------------------------------------
  Baseline                 n=121           n=120                0.838 (0.360)
   Nonadherence            43 (35.0%)      36 (30.0%)           
   Adherence               78 (64.5%)      84 (70.0%)           
  Month 4                  n=109           n=115                7.151 (0.007)[\*](#tfn9-ppa-8-1185){ref-type="table-fn"}
   Nonadherence            48 (44.0%)      31 (27.0%)           
   Adherence               61 (56.0%)      84 (73.0%)           
  Month 8                  n=110           n=102                7.118 (0.008)[\*](#tfn9-ppa-8-1185){ref-type="table-fn"}
   Nonadherence            46 (41.8%)      25 (24.5%)           
   Adherence               64 (58.2%)      77 (75.5%)           
  Month 12                 n=121           n=120                7.238 (0.007)[\*](#tfn9-ppa-8-1185){ref-type="table-fn"}
   Nonadherence            50 (41.3%)      30 (25.0%)           
   Adherence               71 (58.7%)      90 (75.0%)           

**Notes:** *χ*^2^, chi-square test,

statistically significant at *P*\<0.01.

###### 

Comparison of fasting blood glucose and glycated hemoglobin (HbA~1c~) within control and intervention groups over the study period

  Differences           Fasting blood glucose (*z*-value [\#](#tfn10-ppa-8-1185){ref-type="table-fn"} \[*P*-value\])   HbA~1c~ (*z*-value[\#](#tfn10-ppa-8-1185){ref-type="table-fn"} \[*P*-value\])                    
  --------------------- ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------- --------------------------------------------------------------
  Baseline--4 months    −0.761 (0.446)                                                                                 −3.968 (\<0.001)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}                    −1.780 (0.075)   −8.595 (\<0.001)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}
  Baseline--8 months    −1.451 (0.147)                                                                                 −2.784 (0.005)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}                      −0.831 (0.406)   −7.157 (\<0.001)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}
  Baseline--12 months   −1.134 (0.257)                                                                                 −5.909 (\<0.001)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}                    −1.115 (0.265)   −8.265 (\<0.001)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}
  4 months--8 months    −0.109 (0.913)                                                                                 −0.511 (0.609)                                                                  −0.823 (0.411)   −2.728 (0.006)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}
  4 months--12 months   −0.008 (0.994)                                                                                 −2.980 (0.003)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}                      −0.554 (0.580)   −4.831 (\<0.001)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}
  8 months--12 months   −0.268 (0.788)                                                                                 −3.264 (0.001)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}                      −0.159 (0.874)   −4.884 (\<0.001)[\*](#tfn11-ppa-8-1185){ref-type="table-fn"}

**Notes:**

*z*-value, Wilcoxon signed-rank test

statistically significant at *P*\<0.01.

**Abbreviation:** HbA~1c~, glycated hemoglobin.
